ERBB2 and cancer: In those patients that received neoadjuvant chemotherapy (13.2%) therapeutic response measured as residual cancer burden (RCB) was, in general, poor: 13.0% of HR+HER2− patients in this arm of the study had a complete or almost complete pathological response (RCB 0 to 1) (Table 1).